Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease
Launched by KOREA UNIVERSITY ANAM HOSPITAL · Oct 6, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how men and women experience problems with small blood vessels in the heart, specifically in patients who have non-obstructive coronary artery disease. This condition can cause chest pain or other symptoms, even when the main arteries are not blocked. The researchers want to understand if there are differences between sexes in how these small blood vessels work, which could help improve treatment for patients with microvascular angina, a type of chest pain linked to these issues.
To be eligible for the trial, participants should be experiencing chest pain or similar symptoms, but their coronary arteries should not be significantly narrowed (less than 50% blockage). The trial is open to all genders and is currently recruiting patients aged 18 to 75. Participants can expect to have tests done to evaluate the function of their heart's small blood vessels. It's important to note that certain health conditions, like moderate heart valve disease or severe kidney problems, may exclude someone from joining the study. This research aims to find better ways to diagnose and treat heart issues, especially in women, who may experience different symptoms than men.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Typical/atypical chest pain or ischemic symptoms including dyspnea
- • No significant coronary artery stenosis (\<50% stenosis) in coronary angiography or computed tomography
- Exclusion Criteria:
- • ≥ Moderate valvular heart disease
- • Congenital heart disease
- • Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis
- • Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension
- • Receiving anticancer drugs
- • Vasculitis associated with autoimmune diseases
- • Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
About Korea University Anam Hospital
Korea University Anam Hospital is a leading academic medical institution in South Korea renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies that aim to improve patient outcomes and contribute to medical knowledge. With a strong emphasis on ethical practices and patient safety, Korea University Anam Hospital collaborates with various stakeholders to facilitate cutting-edge research across diverse therapeutic areas, fostering an environment that promotes scientific discovery and translational medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Seong-Mi Park, PhD
Principal Investigator
Korea University Anam Hospital
Mi-Na Kim, PhD
Study Chair
Korea University Anam Hospital
Dong-Hyuk Cho, PhD
Study Chair
Korea University Anam Hospital
So Ree Kim, PhD
Study Chair
Korea University Anam Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported